Chaga Mushroom Formulations Using Extraction and Esterification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including conventional drugs and mushroom-based therapies, suffer from low efficacy and significant side effects, and there is a need for more effective, less toxic therapeutic approaches, particularly for human and equine cancers, with betulinic acid from Chaga mushrooms facing challenges due to poor bioavailability.
Innovation Solution
A nutraceutical and medicinal formulation is developed by reducing and extracting Chaga mushrooms in specific solvents, combining the extracts with esterification mixtures containing proline, fructose, and medium chain triglyceride oil, and optionally adding Manuka honey to enhance bioavailability and efficacy, forming novel compounds through Maillard reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then cancer cells can be targeted, but significant side effects and low efficacy occur
Solution Approach 1:
The patent extracts and isolates specific bioactive compounds (betulinic acid, ganoderic acids, polysaccharides, triterpenes) from Chaga mushroom to create targeted therapeutic agents. This extraction process separates the effective components from the whole mushroom material, enabling precise targeting of cancer cells while minimizing unnecessary exposure to other compounds that could cause side effects.
Solution Approach 2:
The patent employs multiple extraction methods with different solvents (water, ethanol, acetone, hexane) and processing conditions (reduction, esterification) to selectively obtain different compounds with specific properties. By changing extraction parameters, the patent optimizes the concentration and purity of active ingredients, thereby enhancing efficacy while controlling toxicity.
2Reliability
If betulinic acid from Chaga mushrooms is used, then anti-cancer activity is achieved, but poor bioavailability limits effectiveness
Solution Approach 1:
The patent creates composite formulations combining betulinic acid with other Chaga mushroom compounds (ganoderic acids, polysaccharides, triterpenes) and uses multiple extraction solvents to produce a synergistic mixture. This composite approach enhances the overall bioavailability and anti-cancer activity compared to using single compounds alone.
Solution Approach 2:
The patent uses various solvents (ethanol, water, acetone) as intermediaries to extract and deliver active compounds from the mushroom material. These solvents act as mediators that facilitate the transfer of hydrophobic and hydrophilic compounds into bioavailable forms that can be effectively absorbed and utilized in the body.
3Reliability
If medicinal mushrooms are used, then immune system support and anti-cancer effects are provided, but limited treatment options exist for advanced-stage cancer
Solution Approach 1:
The patent develops a multi-functional Chaga mushroom formulation that simultaneously provides immunomodulating effects (through polysaccharides and beta-glucans), direct anti-cancer activity (through betulinic acid and ganoderic acids), and synergistic enhancement of conventional therapies. This universal preparation addresses multiple therapeutic needs in a single treatment system.
Solution Approach 2:
The patent merges multiple bioactive compounds from Chaga mushroom (betulinic acid, ganoderic acids, polysaccharides, triterpenes) into a single integrated formulation. This combination approach creates synergistic effects that enhance overall anti-cancer activity and provide broader treatment options for various cancer stages and types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation demonstrates enhanced cytotoxicity and apoptosis-inducing effects on cancer cells, outperforming traditional preparations and addressing the limitations of betulinic acid bioavailability, providing a promising treatment for various cancer types.
Implementation Method 1
A nutraceutical and medicinal formulation is developed by reducing and extracting Chaga mushrooms in specific solvents
Implementation Method 2
forming novel compounds through Maillard reactions
Data Source
AI summary
Medicinal and nutraceutical formulations based on Chaga mushrooms, chemical compounds and pharmaceutical compositions, and methods of production. When administered to a human or animal, the formulations, compounds, and pharmaceutical compositions are useful for the treatment of diseases such as cancers. The nutraceutical formulation includes a reduction of Chaga mushroom, where the reduction is formed in a reduction solvent; and an extraction of Chaga mushroom, where the extraction is formed in an extraction solvent. The reduction and extraction are mixed together or combined in accordance with methods known to those skilled in the art, to form the nutraceutical formulation. The medicinal formulation is a reaction product made by preparing a Chaga mushroom reduction in a reduction solvent under pressure, preparing a Chaga mushroom extraction in an extraction solvent, mixing or combining the Chaga reduction with the Chaga extraction, mixing or combining the Chaga formulation with an esterification mixture containing proline, fructose, and a fatty acid for the development of esterified compounds, and including sources of sugar esters capable of emulsion within otherwise non-miscible liquid compounds, or a predetermined amount of Manuka honey sufficient to cause esterification and facilitate emulsion at a temperature capable of inducing a reaction between the constituents of the Chaga mushroom with the constituents of the esterification mixture or Manuka honey, and combining that heterogenous mixture with medium chain triglyceride oil.